Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly (ADP-ribose) polymerase 1 (PARP1) is a multifunctional nuclear enzyme that plays a central role in DNA repair, chromatin remodeling, transcription regulation, cell cycle control, and programmed cell death. It uses NAD+ to catalyze the transfer of ADP-ribose units onto itself and other target proteins (PARylation). PARP1 acts as a first responder to DNA single-strand breaks (SSBs), binding rapidly to damaged sites and recruiting various DNA repair factors. It is a key target in cancer therapy, particularly in tumors deficient in homologous recombination repair genes like BRCA, where PARP inhibition leads to synthetic lethality.
Inhibition of PARP1 enzymatic activity, leading to synthetic lethality in cells deficient in homologous recombination repair (e.g., BRCA-mutated cancer cells).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly (ADP-Ribose) Polymerase 1 (PARP1).